Drug Delivery Technology: Revolutionizing Cardiovascular Therapies

Published Date: 09/07/2007
Category: Drug Delivery & Devices

Research Report Decription

Sample Pages:

Click here (PDF)

This report gives in depth analysis of innovative drug delivery formulations  and devices that are being applied to novel cardiovascular treatments and implants. These include the evolution of controlled-release formulation, systemic targeted delivery platfroms and delivery in situ via implants, biomaterials and drug eluting stents (DES).

Key Questions Answered:

• How will the drug delivery technology drivers change in the cardiovascular arena during the next decade and beyond?
• What are the key delivery technologies and devices in the cardiovascular field?
• When are products and medical devices which utilize these key delivery technologies likely to reach the market?
• Which drug delivery specialists are forming strategic alliances with the pharma industry in the cardiovascular arena?
• Which companies are the winners in each technology category?
• How are drug delivery technologies evolving to meet the demands of the cardiovascular market?
• Where are the market opportunities now and in the future?

• What do we predict will be the value of the cardiovascular drug delivery and medical devices market each year until 2012, in 2015 and in 2020?

Companies Mentioned:

Abbott Vascular, Actelion Pharmaceuticals, Advanced Cell Technology, Alltracel Technologies, Alnylam Pharmaceuticals, ALZA , Amgen, AnGes MG, Angioblast Systems, Ark Therapeutics, AVI BioPharma Inc, Bard Inc, Bioavail Pharmaceuticals, Bioheart, Biophan Technologies, Biosense Webster, BioSensors International, Biosync Scientific Corporation, Biotechnology Research Corporation of Hong Kong, Biotronik AG, Boston Scientific Inc, Bristol-Myers Squibb, Cardium Therapeutics, Celladon Corporation, Clearstream, Conor Medsystems Inc, Cook Medical, Copernicus Therapeutics, Cordis Corporation, Cytori Therapeutics, Diachii-Sankyo, Dendritic Nanotechnologies, DepoMed Inc, EMD BioSciences (Merck KGaA), Emisphere Technologies, EndoTex Interventional Systems, Endovasc, GlaxoSmithKline, Geron Corporation, Guidant Corporation, ImaRx Therapeutics, Infigen Inc., Innocore Technologies, Invitrogen, Johnson & Johnson, Kereos, Maxcyte, Medtronic Inc, Merck & Co., MG Biotherapeutics, Micell Technologies, Miravant Medical Technologies, Mirus Bio Corporatiom, MIV Therapeutics, Myosix, Mytogen Inc., Nastech Pharmaceutical, NaturalNano Inc, Northern Therapeutics, Novartis, OBS Medical, OrbusNeich, Osiris Therapeutics, Otsuka, Pacific Northwest National Laboratory, Penwest Pharma, Phosphagenics Ltd, Pfizer, PolyNovo, Protiva Biotherapeutics, pSivida, Remon Medical Technologies Inc, Resverlogix Corporation, Sanofi-aventis, Schering-Plough, SCOLR Pharma, StarPharma, SurModics Inc, Tissue Genesis Inc, TyRx Pharma, UCB, Vical Inc, Volcano Corporation, X-Cell Medical Inc.

Paper Highlights:

• 2006 global cardiovascular market worth over US$75 billion.
• The market has attracted attention of specialty pharma and big pharma players such as Amgen, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Sanofi-aventis and Schering-Plough.
•  >270 products in clinical development however; 3 key challenges remain - ensuring efficient, targeted and controlled-release of mono- and combination therapies, improve delivery of novel regenerative therapies and improve the biocompatibility & biodegradability of medical devices.
• Analysis of historic (2000-2005) market trends of the cardiovascular pharmaceutical sales and advanced drug delivery sales.
• Forecasts for near-term (2006-2012) and the future (2020) market growth based on the technology platforms evaluated in the report.
• Plus, sales forecasts for approved and pipeline cardiovascular products and medical devices used as a basis for our cardiovascular drug delivery sales (CDDS) forecasts.
• Drug delivery companies applying a plethora of platforms, including controlled-release, targeted systems, to overcome the above challenges.
• Many new classes of drugs and combinations will reach the market over the next 6 years, driving future market growth. Their success is analyzed in detail and case studies provided to highlight the progress of each technology.
• As the cardiovascular market evolves new approaches to treatment will emerge targeting the reversal of cardiovascular conditions utilizing cutting edge cell- and gene based therapies. Several Biotherapeutic companies are working towards this goal including: Advanced Cell Technology, Angioblast Systems, Cytori Therapeutics, Geron Corporation, MG Biotherapeutics, Osiris Therapeutics and Tissue Genesis. A number of delivery options are currently being evaluated to optimize the clinical utility of these regenerative therapies and are analyzed in detail in the report.

• The medical devices market is going through a transition period as novel biomaterials are evaluated that may have wide ranging utility in medical devices including drug eluting stents. Competition in this market is fierce where Abbott Laboratories, Boston Scientific Corporation, Johnson & Johnson and Medtronic dominae but newer players such as MIV Therapeutics are venturing into the arena. The latest development in drug-eluting stents and biomaterials are analyzed in detail in the report.